Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly stock jumps 4% premarket on news of positive results in late-stage trial of Alzheimer's disease treatment
06:14am, Wednesday, 03'rd May 2023
Eli Lilly & Co.'s stock LLY jumped 4% premarket Wednesday, after the company announced positive data from a late-stage trial of its Alzheimer's disease treatment donanemab. The company said the Phase
3 Stocks Quietly Hitting All-Time Highs (and Can Continue Higher)
06:00am, Wednesday, 03'rd May 2023
It's been a tough 12 to 18 months for investors. The market roared higher into the end of 2021, stumbled big time in 2022, and had a strong start to 2023.
Eli Lilly Alzheimer's treatment donanemab slowed disease progression in clinical trial
06:00am, Wednesday, 03'rd May 2023
Donanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
01:12pm, Tuesday, 02'nd May 2023
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.
Is Eli Lilly a Smart Dividend Stock to Buy Now?
09:45am, Tuesday, 02'nd May 2023
Eli Lilly is facing stiff but short-term headwinds to its earnings. Its dividend isn't in any danger, and it'll likely continue to rise -- and quickly.
EIi Lilly's weight-loss drug is 'much better' than others on the market, says Wells Fargo's Bansal
06:32pm, Monday, 01'st May 2023
Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to discuss Eli Lilly's recent stock performance as demand for its weight-loss drugs climb.
V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023
04:51pm, Monday, 01'st May 2023
The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-ye
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease
09:00am, Sunday, 30'th Apr 2023
Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
Why Eli Lilly Stock Was a Winner Today
06:11pm, Friday, 28'th Apr 2023
The pharmaceutical company benefitted from a clutch of analyst price-target raises. These followed Lilly's well-received earnings report.
Weight loss drug market is just beginning to take off, says Mizuho's Jared Holz
02:33pm, Friday, 28'th Apr 2023
Jared Holz, Mizuho healthcare equity strategist, joins 'The Exchange' to discuss new weight loss drugs coming to market, forecasts for market expansion in weight loss drugs, and key players in the wei
5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
05:21am, Friday, 28'th Apr 2023
The Federal Reserve is now forecasting a mild recession for later this year. When uncertainty picks up, investors typically flock to safe stocks.
Is Eli Lilly Stock a No-Brainer Buy After Mounjaro's Latest Big Win?
05:49pm, Thursday, 27'th Apr 2023
Lilly is now racing toward likely approval for Mounjaro in treating obesity after positive late-stage results. The bigger picture for the company also looks good overall.
Analyst discusses weight loss drugs and why he's bullish on Eli Lilly
05:39pm, Thursday, 27'th Apr 2023
Evan Seigerman, BMO Capital Markets Managing Director of BioPharma Equity Research, joins Yahoo Finance Live to discuss why investors are becoming bullish on weight-loss drug opportunities and the out
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
03:57pm, Thursday, 27'th Apr 2023
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
Eli Lilly stock rises after 1Q revenue beat and pipeline momentum from diabetes and weight loss drug Tirzepatide
11:31am, Thursday, 27'th Apr 2023
Eli Lilly & Co stock climbed after the drug maker reported first-quarter earnings showing a revenue beat and raised its full-year guidance. For the quarter ended March 31, 2023, the Indianapolis-based
